Merck MRK-0.26%decrease; red down pointing triangle is shaking up the leadership of its main pharmaceutical unit as the U.S. drugmaker braces for sales pressure later this decade. The Rahway, ...

Merck (MRK) announced plans to separate its core pharmaceutical division into two units as it prepares for the upcoming patent expiration of its top-selling drug. The drugmaker said it is organizing ...

Merck said on Monday it would split its business into two, creating ⁠a distinct division for its cancer franchise led by blockbuster drug Keytruda while grouping its non-oncology treatments separately ...

Merck to split business into oncology and non-oncology units Split does not involve its animal health division Key patents on Keytruda will begin to expire in 2028 Feb 23 (Reuters) - Merck (MRK.N), ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug. Merck is separating its human health business into two core areas, with oncology ...

Merck & Co. is reorganizing its main pharmaceutical business in a bid to better prepare for a patent “cliff” threatening a large chunk of its future revenue. The big drugmaker on Monday said it’s ...

Gideon Korrell is a seasoned attorney with more than 15 years of experience and a distinctive background in nuclear power and defense engineering. ROSS, CA, UNITED ...